CA-AVIATRIX
22.2.2021 15:02:12 CET | Business Wire | Press release
Aviatrix , the cloud network platform, today announced that James Devine, formerly from AWS, has joined the company as a Principal Solutions Architect. While at AWS, Devine co-authored the AWS Certified Advanced Networking Study Guide and played an active role in defining cloud reference architectures for some of largest AWS customers. The company also recently added other cloud networking luminaries to its elite Solutions Architecture & Engineering team, including two former Microsoft Azure network specialists, with “Global Black Belt for Azure Networking,” classification; Manny Calero and Bryan Ashley (2 of only 10 people in the world that have this status), along with John Gonsalves, Citigroup’s former Global Head of Network Engineering.
Members of the Aviatrix Solutions Architecture & Engineering team share a common passion for cloud networking, security, and operational simplicity. This team fully understands each customer’s vision and challenges associated with cloud transformation, and helps organizations design and solve complex cloud networking and security problems in a simple and innovative way, the right way, the cloud way.
“I’m very excited to join the Aviatrix team,” said James Devine, Principal Solutions Architect at Aviatrix. “In my previous role as a networking specialist at AWS, I’ve actually recommended Aviatrix to numerous customers where the AWS platform alone couldn’t provide the visibility, control and multi-cloud capabilities they were looking for. I love working with customers, helping them design their cloud network strategies, and by using Aviatrix, our customers will experience a much smoother and more pleasant experience as they transition to multi-cloud.”
These significant additions to the Aviatrix team further validate the company’s cloud network platform, its MCNA (Multi-cloud Network Architecture) approach, and the rapid innovation that Aviatrix is bringing to cloud networking. As transformation to multi-cloud is quickly becoming essential for every organization, customers are demanding more advanced networking capabilities with a simple repeatable architecture that extends to multiple regions and multiple clouds. The top talent that Aviatrix is attracting is driving the future of cloud networking by bringing simplicity, security, operational efficiency, and advance controls for our customers. James, Manny, Bryan, and John, along with existing members of the Solutions Architecture & Engineering team, are playing a key role in defining product direction and helping with cloud architecture and design for some of the world’s largest brands. They’re also developing multi-cloud network training as part of the company’s well-recognized and respected “ACE Program ,” which recently surpassed 10k certified engineers in just under a year. This program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals.
“We’re thrilled to have James join our team,” stated Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “Our elite group of cloud networking experts has many years of expertise in designing and managing network infrastructures. And now they’ve all joined Aviatrix with one thing in common – to provide the best cloud networking solutions and experience to our customers.”
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005214/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
